Latest & greatest articles for terazosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on terazosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on terazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for terazosin

1. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. (Abstract)

Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. Thirteen patients with essential hypertension were treated with an alpha 1-adrenoceptor antagonist, terazosin (1 to 4 mg/day) for 12 months. To assess the mechanism of its antihypertensive effect, the hemodynamic and endocrinological responses to terazosin were determined before, 3, and 12 months after the administration (...) of terazosin. Blood pressure significantly decreased within 2 weeks after the start of terazosin and its effect was sustained throughout the 12 month period. Pulse rate did not change except slight increase in the third month. The hemodynamic studies revealed that total peripheral resistance significantly decreased and cardiac output slightly increased, indicating that the antihypertensive effect of terazosin is mainly produced by its vasodilation. Blood volume and plasma volume did not change. Although

1990 American journal of hypertension

2. A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. (Abstract)

A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).A total of 115 patients with category III CP/CPPS receiving 6-week therapy were randomly divided into the levofloxacin group (n = 38), terazosin group (n = 38 (...) ), and combination group (n = 39). The primary endpoint was the response rate (i.e., the change from baseline) in the total and domain scores of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Secondary endpoints were expressed as prostatic secretion-white blood cell (EPS-WBC) and International Index of Erectile Function-5 (IIEF-5).After 6 weeks, the response rate of NIH-CPSI scores was 45.1, 22.4, and 50.0 % in the levofloxacin group, terazosin group, and combination group

2015 International urology and nephrology Controlled trial quality: uncertain

3. Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/ (Abstract)

Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/ 27378099 2019 03 11 2019 03 11 1573-2584 49 3 2017 03 International urology and nephrology Int Urol Nephrol Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized (...) controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. Int Urol Nephrol. 2016;48:13-18. 457-458 10.1007/s11255-016-1356-2 Papeš Dino D Department of Surgery, Clinical Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia. dinopapes@gmail.com. Pasini Miram M Department of Surgery, Clinical Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia. Jerončić Ana A Department of Research in Biomedicine

2017 International urology and nephrology Controlled trial quality: uncertain

4. [Therapy of benign prostatic hyperplasia: terazosin or finasteride?]. (Abstract)

[Therapy of benign prostatic hyperplasia: terazosin or finasteride?]. 9381019 1997 11 14 2013 11 21 1661-8157 86 34 1997 Aug 20 Praxis Praxis (Bern 1994) [Therapy of benign prostatic hyperplasia: terazosin or finasteride?]. 1305-6 Trinkler F B FB Urologische Klinik, Universitätsspital, Zürich. ger Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Therapie der benignen Prostatahyperplasie: Terazosin oder Finasterid? Switzerland Praxis (Bern 1994 (...) ) 101468093 1661-8157 0 Adrenergic alpha-Antagonists 0 Enzyme Inhibitors 57GNO57U7G Finasteride 8L5014XET7 Terazosin XM03YJ541D Prazosin IM Adrenergic alpha-Antagonists administration & dosage adverse effects Double-Blind Method Enzyme Inhibitors administration & dosage adverse effects Finasteride administration & dosage adverse effects Humans Male Prazosin administration & dosage adverse effects analogs & derivatives Prospective Studies Prostatic Hyperplasia drug therapy Urodynamics drug effects 1997 8

1997 Praxis Controlled trial quality: uncertain

5. Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. (Abstract)

Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. 8583558 1996 03 19 2017 09 08 0022-5347 155 3 1996 Mar The Journal of urology J. Urol. Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. 1039 Frankel G G eng Comment Letter United States J Urol 0376374 0022-5347 0 Adrenergic alpha-Antagonists 8L5014XET7 Terazosin XM03YJ541D Prazosin AIM IM J Urol

1996 The Journal of urology Controlled trial quality: uncertain

6. The influence of food on the oral bioavailability of terazosin. (Abstract)

The influence of food on the oral bioavailability of terazosin. 1685091 1992 02 27 2018 11 13 0306-5251 32 6 1991 Dec British journal of clinical pharmacology Br J Clin Pharmacol The influence of food on the oral bioavailability of terazosin. 775-6 McNeil J J JJ Drummer O H OH Raymond K K Conway E L EL Louis W J WJ eng Clinical Trial Letter Randomized Controlled Trial Research Support, Non-U.S. Gov't England Br J Clin Pharmacol 7503323 0306-5251 0 Adrenergic alpha-Antagonists 8L5014XET7 (...) Terazosin XM03YJ541D Prazosin IM Administration, Oral Adrenergic alpha-Antagonists pharmacokinetics Adult Biological Availability Food Humans Middle Aged Prazosin analogs & derivatives pharmacokinetics 1991 12 1 1991 12 1 0 1 1991 12 1 0 0 ppublish 1685091 PMC1368564 Br J Clin Pract Suppl. 1987 Dec;54:9-14 2905162 Am J Med. 1986 May 23;80(5B):20-4 2872802 Clin Pharmacokinet. 1980 Nov-Dec;5(6):583-90 7438656 Prostate Suppl. 1990;3:75-84 1689172 Am J Cardiol. 1990 Mar 1;65(9):638-43 1968703 J Cardiovasc

1992 British journal of clinical pharmacology Controlled trial quality: uncertain

7. Terazosin

Terazosin Top results for terazosin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for terazosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

8. Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting (TZ-CAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03195673 Recruitment Status

2017 Clinical Trials

9. WITHDRAWN: Terazosin for benign prostatic hyperplasia. (Abstract)

WITHDRAWN: Terazosin for benign prostatic hyperplasia. Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker, terazosin, for treatment of urinary symptoms associated with BPO.Trials were searched (...) in computerized general and specialized databases (MEDLINE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers.Studies were included if they (1) were randomized trials of at least 1 month duration, and (2) included men with symptomatic BPO and compared terazosin with placebo or active controls.Study, patient characteristics and outcomes data were extracted in duplicate onto standardized forms utilizing a prospectively developed protocol. The main outcome measure

2011 Cochrane

10. The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms

The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01530243 Recruitment Status : Completed First Posted : February 9, 2012 Results First Posted : March 2, 2015 Last Update Posted : March 2, 2015 Sponsor: Urmia University of Medical

2012 Clinical Trials

11. Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00237510 Recruitment Status : Completed First Posted : October 12, 2005 Last Update Posted : March 5, 2014 Sponsor: Thomas Jefferson University Information

2005 Clinical Trials

12. Effects of Terazosin on Glycemic Control, Cholesterol, and Microalbuminuria in Patients with Non--Insulin-Dependent Diabetes Mellitus and Hypertension. (Abstract)

Effects of Terazosin on Glycemic Control, Cholesterol, and Microalbuminuria in Patients with Non--Insulin-Dependent Diabetes Mellitus and Hypertension. The use of antihypertensive agents that have positive or neutral effects on blood sugar, lipid profiles, and microalbuminuria can be important clinical treatment for patients with diabetes. We evaluated the effects of both terazosin, a selective alpha-one-adrenergic blocker, and hydrochlorothiazide (HCTZ), a standard mild antihypertensive agent (...) , on glycemic control, urinary albumin excretion rate overnight total cholesterol, and other parameters in non--insulin-dependent diabetes mellitus (NIDDM) patients. A randomized, placebo-controlled, cross-over design was implemented in 25 patients. Over an 8-week treatment period fasting plasma glucose (FPG) and glycosylated hemoglobin (GHgb) improved in the terazosin group. Post-treatment FPG was 200 plus minus 85 and 187 plus minus 71 for patients who received HCTZ and terazosin, respectively. Although

1996 American journal of therapeutics Controlled trial quality: uncertain

13. Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2007 Clinical Trials

14. Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension

Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00693199 Recruitment Status : Completed First Posted : June 6, 2008 Last Update

2008 Clinical Trials

15. Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin (ADIES) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00449683 Recruitment Status : Completed First Posted : March 20, 2007 Last Update Posted : August 25, 2016 Sponsor: Thomas Jefferson

2007 Clinical Trials

16. Use of terazosin in prostatodynia and validation of a symptom score questionnaire. (Abstract)

Use of terazosin in prostatodynia and validation of a symptom score questionnaire. The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease.Twenty-five patients who presented with lower urinary tract symptoms suggestive of prostatitis were evaluated for evidence of bacterial infection by Meares-Stamey criteria and found to be negative. They were then treated with the alpha-blocking drug (...) terazosin in doses from 1 to 10 mg. A symptom score index for prostatitis was developed, tested in these patients, and validated against patients with benign prostatic hyperplasia. Normal control patients, who presented for vasectomy, were studied as well.Nineteen patients (76%) responded to one month's therapy, with 11 (58%) remaining asymptomatic three months later. The symptom score index, as measured by Cronbach's alpha measure of index reliability, was excellent at 0.78 and logistic regression

1994 Urology

17. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy]. (Abstract)

[A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy]. In this study the multicenter, fixed-flexible dose regimen was taken to evaluate the effective dose range of Terazosin for the treatment of micturition disturbance in benign prostatic hypertrophy (BPH) and to clarify the characteristics of patients who are more responsive to Terazosin therapy. After a 1-week washout (placebo) the first two weeks 1 mg/day (...) of Terazosin was administered, then depending on efficacy of subjective symptoms, Terazosin doses were increased up to 2 mg/day and 4 mg/day at intervals of two weeks. After six weeks the final efficacy and safety were assessed. The subjective symptom improvement rate was 18.5% by 1 mg/day, 55.6% by 2 mg/day and 65.4% by 4 mg/day cumulatively. The objective symptom improvement rate were 13.2% by 1 mg/day, 42.1% by 2 mg/day and 50.0% by 4 mg/day cumulatively. The global improvement rate was 14.5% by 1 mg

1992 Hinyokika kiyo. Acta urologica Japonica

18. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. (Abstract)

The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Pharmacotherapy for the treatment of BPH is currently being targeted to relax prostate smooth muscle (alpha blockade) and decrease prostate volume (androgen suppression). The objective of the present study was to determine the relative efficacy of terazosin vs. terazosin and flutamide (combination therapy) for the treatment of symptomatic BPH. Twenty-nine males with symptomatic BPH were (...) enrolled into this 6-month open label study. The entry criteria included peak urinary flow rate between 4-15 ml/sec, a total Boyarsky symptom score greater than 7, and postvoid residual less than 300 ml. The daily dosage of terazosin was titrated to 5 mg over a 2-week interval. A 750 mg daily dosage of flutamide was added following 1 month of terazosin monotherapy. The dosages were lowered if significant adverse events developed. Efficacy assessments were performed at 1 month (terazosin alone), 6

1992 Prostate

19. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. (Abstract)

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. To evaluate long-term efficacy and safety of terazosin, a selective alpha 1 blocker, in the treatment of benign prostatic hyperplasia (BPH).This was a long-term (42 months), open-label, multicenter study with patients evaluated at 1- to 6-month intervals. Twenty-three outpatient clinics throughout the United States and Canada participated in the study. A total of 494 men (...) with symptomatic BPH, lacking absolute indications for surgery, were enrolled in this study; 298 were transferred into the study from randomized, placebo-controlled studies of terazosin and 196 had no prior terazosin therapy. Terazosin was given starting at 1 mg/d and titrated upward until symptoms were relieved or a maximum dose of 20 mg/d was achieved, whichever came first.Peak urinary flow rates at all visits were significantly higher than baseline values, with mean improvements ranging from 1.0 to 4.0 mL/s

1995 Urology

20. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. (Abstract)

Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Antihypertensive effect, platelet aggregation, and plasma lipid profile were studied in a group of 14 hypertensive patients with diastolic blood pressure between 96 and 116 mm Hg during placebo and terazosin phases. Terazosin, an alpha 1-adrenergic blocking agent, was given initially at the dosage of 1 mg daily. Then it was continued at a dosage of 2 mg daily and 5 mg daily respectively, each (...) dosage for 4 weeks. Blood pressure was taken every 2 weeks. Ex vivo platelet aggregation induced by epinephrine, collagen, and adenosine diphosphate (ADP) were carried out twice during the first placebo phase, once at the end of each terazosin dosage, and once in the second placebo phase. Total cholesterol, HDL cholesterol, and triglycerides were measured at the end of first placebo and terazosin phases. Blood from eight patients was taken during the second placebo phase to carry out in vitro

1996 American journal of hypertension